The main objective of the CARE-ANEURYSM project is to evaluate inflammation and clotting abnormalities in patients with aneurysmal coronary artery disease in relation to patients with abdominal aortic aneurysm or coronary artery disease (acting as controls).
The trial will enrol 180 patients, 60 in each of three groups: 1) aneurysmal coronary artery disease; 2) abdominal aortic aneurysm; 3) coronary artery disease. In addition, up to 250 patients with aneurysmal coronary disease will be follow for clinical outcomes in relation to controls (prognosis group). The primary research question of this project is to evaluate wheter the inflammation and clotting abnormalities in patients with aneurysmal coronary artery disease differ from ones in abdominal aortic aneurysm or coronary artery diseases. Study endpoints include the level of inflammation biomarkers and fibrin clot properties in each cohort.
Study Type
OBSERVATIONAL
Enrollment
180
Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
Department of Cardiac and Vascular Diseases, John Paul II Hospital
Krakow, Poland
RECRUITINGInflammation
Level of inflammation biomarkers (such as 8-isoprostane, Il-6) in each group
Time frame: Baseline (at enrolment)
Clotting
Fibrin clot properties (such as clot lysis time, clot permeability) in each group
Time frame: Baseline (at enrolment)
Composite Clinical outcome after 1 year
Death, stroke, myocardial infarction
Time frame: 1 year after the enrolment
Composite Clinical outcome after 5 years
Death, stroke, myocardial infarction
Time frame: 5 years after the enrolment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.